The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Publications & Articles

European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission
The Lancet Oncology, November 2022

Cancer World publication: Mark Lawler comments on the conclusions of a UK consensus group (September 2022)

United efforts to accelerate drug development
European Pharmaceutical Review, December 2021

Access to Personalised Oncology in Europe : a report by LSE consulting, commissioned by EFPIA and contributed by the CDDF (November 2020)

ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer
Cancerworld, September 2020

Verweij, J., Hendriks, H.R., Zwierzina, H. (2019) – on behalf of the CDDF. Innovation in oncology clinical trial designCancer Treatment Reviews, 74, 15-20.

Biomarkers and patients’ access to personalised oncology drugs in Europe
Open Access Government, January 2019

The use of real-world data in cancer drug development
European Journal of Cancer (EJC), Volume 101, pp. 69-76, September 2018
Access the article in PDF format.

The Current and Future Challenges of Personalised Cancer Therapy
Open Access Government, April 2018

5th Immunotherapy of Cancer Conference (ITOC5), 19-21 March 2018, Berlin, Germany – Abstract Book
European Journal of Cancer (EJC), Volume 92, Supplement 1, S1-S26, March 2018

Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Oncotarget, doi: 10.18632/oncotarget.17397, April 2017

4th Immunotherapy of Cancer Conference (ITOC4), 20-22 March 2017, Prague, Czech Republic – Abstract Book
Journal for Immunotherapy of Cancer 2017 5 (Suppl 1):12, 20 March 2017

Accelerating progress in immunotherapy
Cancerworld, n°71 –  Cutting Edge section, pp. 29, March, April, 2016

Regulators Embrace Immunotherapy
J. Smyth – The ASCO Post, 25 March 2016

3rd Immunotherapy of Cancer Conference (ITOC3), 21-23 March 2016, Munich, Germany – Abstract Book
European Journal of Cancer (EJC), Volume 55, Supplement 1, March 2016

Access to innovative oncology medicines in Europe
L. Bergmann, H. Enzmann, S. Thirstrup, J. K. Schweim, I. Widera, and H. Zwierzina
Ann. Onc. 2016 27: 353-356, November 2015

2nd Immunotherapy of Cancer Conference (ITOC2), 25-27 March 2015, Munich, Germany – Abstract Book
European Journal of Cancer (EJC), Volume 51, Issue S1, pp. S1-S14, March 2015

Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer
European Journal of Cancer (EJC), Volume 51, Issue 2, pp. 218-224, January 2015

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70